Pronounced “BULL-us PEM-fih-goyd” (with bullous being the medical term for a large blister), Bullous Pemphigoid is a rare, autoimmune, chronic skin disorder that causes large, fluid-filled blisters.

Bullous pemphigoid, an immune-mediated condition characterized by large, fluid-filled blisters on the skin, is a rare but serious complication of cancer therapy with immune checkpoint inhibitors (ICIs ...

Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...

PV is characterized by the deposition of IgG antibodies against desmoglein 3 (Dsg3, a 130kDa protein) and desmoglein 1 (Dsg1) found in the mucous epithelium and in skin desmosomes, causing loss of ...

(RTTNews) - Drug makers Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Wednesday that ADEPT study of Dupixent (dupilumab) in bullous pemphigoid or BP met the primary and all key ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...

Please provide your email address to receive an email when new articles are posted on . Dupixent previously received priority review and orphan drug designation from the FDA for bullous pemphigoid.

More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...

A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. On the same day the companies unveiled positive data from a study in chronic spontaneous urticaria (CSU) and a new ...